A to Z / Approved medicine
Setmelanotide
Also known as Imcivree, RM-493.
Best known for The melanocortin drug for rare genetic obesity
Evidence★★★★★
Safety dataWell characterised
Route Daily subcutaneous injection
United StatesFDA approved (rare genetic obesity)
AustraliaSchedule 4: prescription only
as at 16 September 2026
What it is and what it does
Setmelanotide is an MC4R agonist approved for obesity caused by specific rare genetic defects in the melanocortin pathway, including POMC, PCSK1 and LEPR deficiency, and Bardet-Biedl syndrome.
What the full entry covers
The book carries the rest of this entry:
- Where the research stands, with every claim cited
- What people commonly ask, and what the research shows so far
- Dosing in four labelled bands, described and not recommended
- Side effects, serious risks, cautions and interactions
- Questions to discuss with your doctor
- How it compares with PT-141, Melanotan II, Semaglutide, Bremelanotide Analogues
Related entries
A certificate of analysis tells you what is in a vial. The evidence rating above tells you whether the compound has been shown to work in humans. Neither answers the other's question. How to read a certificate of analysis.
This page describes what is known and not known about Setmelanotide. It is not medical advice and not a recommendation to use it.